Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion.
High-Dose Eylea Fails to Defend Share: Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Strong Buy. The downside is fundamentally fully priced in, while the long-term compounder cash profile remains robust and highly intact.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
In a severe downside scenario, Regeneron faces simultaneous shocks: Eylea loses material share to Vabysmo and biosimilars, Dupixent growth sharply decelerates, and pipeline failures force a structural reset in operating margins below 25%. Even under these dire conditions, baseline FCFF generation anchors intrinsic value near $917, indicating the downside is already heavily priced in.
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Scale advantages in manufacturing and clinical trial execution versus smaller biopharma peers.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $4.4B after capex $717.1M, with terminal value at 68.5% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Regulatory pricing pressures compound with aggressive biosimilar substitution, severely discounting terminal multiples across mature biopharma.
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
Core holding for large-cap growth allocations. Sizing should confidently reflect the robust margin of safety.
Trim exposure if shares approach the $1,200 fair value mid-point, or if high-dose Eylea fails to retain 50%+ share over a 12-month trailing period.
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
The 38.2% gap versus the $875.31 internal valuation cross-checks underscores a myopic market fixation on transient R&D spending and peak patent cliff fears, completely ignoring the underlying cash-generation power of VelociSuite.
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
In a downside event where core assets erode rapidly and R&D fails to deliver, the stock still holds a baseline value of $917, highlighting the massive margin of safety currently priced into the $714 level.
Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
Dupixent matures faster than expected and label expansions underperform, halting the company's primary top-line engine.
Elevated R&D spend of $5.8B yields zero meaningful commercial blockbusters, structurally degrading long-term ROIC and locking in compressed margins.
The five developments that would weaken our investment case.
Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
Current:Baseline adoption as of 2026-05-10
Alert ifStalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window
Top-line contraction signals that primary immunology volume growth has matured or faced commercial resistance, leaving insufficient organic momentum to offset legacy product patent cliffs.
Current:1.0% for the period ended 2025-12-31
Alert ifDecelerates below 0.0% over any trailing twelve-month period
A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
Current:25.8% for the period ended 2025-12-31
Alert ifCompresses below 25.0% over any trailing twelve-month period
Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Current:$5.8B annual R&D spend as of 2026-05-10
Alert ifFiled clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window
A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
Current:12.3% as of 2026-05-10
Alert ifBreaks below 10.0% as of any annual measurement date
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.
Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.
Warning level: Stalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window. Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
Warning level: Decelerates below 0.0% over any trailing twelve-month period. Top-line contraction signals that primary immunology volume growth has matured or faced commercial resistance, leaving insufficient organic momentum to offset legacy product patent cliffs.
Warning level: Compresses below 25.0% over any trailing twelve-month period. A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
Warning level: Filed clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window. Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Warning level: Breaks below 10.0% as of any annual measurement date. A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
| — |
| $12.17B |
| $13.12B |
| $14.20B |
| $14.34B |
| +5.6% |
| Gross profit | — | $10.61B | $11.30B | $12.23B | $12.24B | +4.9% |
| Operating income | — | $4.92B | $4.27B | $4.84B | $5.27B | +2.4% |
| Net income | — | $4.34B | $3.95B | $4.41B | $4.50B | +1.3% |
| EPS (diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | -12.9% |
| EBITDA | — | $5.26B | $4.69B | $5.32B | $5.82B | +3.4% |
| R&D | — | $3.85B | $4.63B | $5.23B | $5.85B | +15.0% |
| SG&A | — | $2.12B | $2.63B | $2.95B | $2.70B | +8.5% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 14,342,900,000 |
|---|---|
| Cost of revenue | 2,100,700,000 |
| Gross profit | 12,242,200,000 |
| Operating expenses | 8,540,200,000 |
| Operating income | 3,702,000,000 |
| Non-operating items and tax | 802,900,000 |
| Net income | 4,504,900,000 |
| Total assets | 40,558,700,000 |
|---|---|
| Cash | 3,118,100,000 |
| Current assets | 18,021,900,000 |
| Total liabilities | 9,301,800,000 |
| Current liabilities | 4,368,400,000 |
| Shareholders’ equity | 31,256,900,000 |
Point-in-time financial data used in the 2026-05-10 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — | — | — | — | — | — | — |
| 2022-12-31 | 12.2B | 5.3B | 4.3B | 5B | 3.4B | 1.6B | 341.4M | 725M | 2.5B | — | 0 | — | — | — | — | 3.1B | 2.7B | 38.9% | — | 6.3% | — |
| 2023-12-31 | 13.1B | 4.7B | 4B | 4.6B | 3.7B | 926.4M | 421M | 885M | 2.9B | 0 | — | — | — | — | — | 2.7B | 2.7B | 30.9% | — | 6.2% | — |
| 2024-12-31 | 14.2B | 5.3B | 4.4B | 4.4B | 3.5B | 881.6M | 482.9M | 982.8M | 3.6B | 0 | — | — | — | — | — | 2.5B | 2.7B | 28.1% | — | 6.6% | — |
| 2025-12-31 | 14.3B | 5.8B | 4.5B | 5B | 3.8B | 1.2B | 543.7M | 993.7M | 4B | 370.3M | — | — | — | — | — | 3.1B | 2.7B | 25.8% | — | 7.7% | — |
REGN trades at 13.3x forward earnings against a peer median of 19.9x; EV/EBITDA of 15.2x against a peer median of 20.8x; 6 peers.
| Accumulate aggressively at current levels ($714), as the market is overly penalizing transient R&D investments. |
This edition does not contain enough finite inputs to reproduce the lens calculation.
This edition does not contain enough finite inputs to reproduce the lens calculation.
This edition does not contain enough finite inputs to reproduce the lens calculation.
| MRNA |
| Moderna Inc. |
| -13.1x |
| 9.7x |
| -7.7x |
| -36.6% |
| -131.1% |
| INCY | Incyte Corporation | 10.9x | 3.7x | 10.1x | 30.8% | 25.6% |
| TECH | Bio-Techne Corporation | 23.2x | 6.3x | 20.9x | 5.3% | 25.2% |
| LLY | Eli Lilly and Company | 21.4x | 11.7x | 24.4x | 107.5% | 49.4% |
